Role of the newer alpha, -adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms

Clinical Therapeutics

Volumn 26, Issue 11, 2004, Pages 1701-1713

  Lowe, Franklin C ^a  

^a USA ^*  (United States)

Author keywords

adrenergic receptor antagonist; complications; hypertension; prostatic hyperplasia

Indexed keywords

ALFUZOSIN; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; PRAZOSIN; TAMSULOSIN; TERAZOSIN;

ASTHENIA; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIZZINESS; DRUG EFFICACY; HUMAN; MEDLINE; NONHUMAN; ORTHOSTATIC HYPOTENSION; PROSTATE HYPERTROPHY; REVIEW; URINARY TRACT DISEASE;

EID: 11844264906     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2004.11.006     Document Type: Article

References (93)

1. Boyle P., and Napalkov P. The epidemiology of benign prostatic hyperplasia and observations on concomitant hypertension Scand J Urol Nephrol Suppl. 168 1995 7 12
2. Berry S.J., Coffey D.S., Walsh P.C., and Ewing L.L. The development of human benign prostatic hyperplasia with age J Urol. 132 1984 474 479
3. Garraway W.M., Collins G.N., and Lee R.J. High prevalence of benign prostatic hypertrophy in the community Lancet 338 1991 469 471
4. Coffey D.S. Controversies in the management of lower urinary tract symptoms: An overview Br J Urol 81 Suppl 1 1998 1 5
5. Kirby R.S. The natural history of benign prostatic hyperplasia: What have we learned in the last decade? Urology 56 Suppl 1 2000 3 6
6. Curkendall S.M., Jones J.K., Glasser D., and Goehring E. Incidence of medically detected erectile dysfunction and related diseases before and after Viagra® (sildenafil citrate) Eur Urol. 37 Suppl 2 2000 81
7. Abstract 1365 Rosen R., O'Leary M., and Altwein J. Ejaculatory disorders are frequent and bothersome in ageing males with LUTS: A worldwide survey (MSAM-7) J Urol 169 Suppl 4 2003 365
8. Bansal S. Sexual dysfunction in hypertensive men. A critical review of the literature Hypertension 12 1988 1 10
9. Flack J.M. The effect of doxazosin on sexual function in patients with benign prostatic hyperplasia, hypertension, or both Int J Clin Pract 56 2002 527 530
10. O'Leary M.P. Quality of life and alpha-blocker therapy: An important consideration for both the patient and the physician Urology 59 Suppl 1 2002 7 11
11. Abstract 10 Richard F., Jardin A., and Lukacs B. Results of an epidemiological survey in 3,500 French men aged 50 to 80 years with a special attention to urinary symptoms, quality of life and sexual function Eur Urol 37 Suppl 2 2000 3
12. (Suppl) Richard F., Lukacs B., and Jardin A. Assessing sexual function and urinary symptoms: Results of an epidemiological survey in 3,500 French men aged 50 to 80 years Abstract 1108 J Urol. 163 2000 249
13. Lowe F.C. Goals for benign prostatic hyperplasia therapy Urology 59 Suppl 1 2002 1 2
14. Reid J.L. Drug treatment antihypertensive dings-the present role of beta blockers and alpha blockers Clin Exp Hypertens 21 1999 815 821
15. Caine M., Pfau A., and Perlberg S. The use of alpha adrenergic blockers in benign prostatic obstruction Br J Urol 48 1976 255 263
16. Akduman B., and Crawford E.D. Terazosin, doxazosin, and prazosin: Current clinical experience Urology 58 Suppl 1 2001 49 54
17. Rhodes P.R., Krogh R.H., and Bruskewitz R.C. Impact of ding therapy on benign prostatic hyperplasia-specific quality of life Urology 53 1999 1090 1098
18. Engstrom J.W., and Aminoff M.J. Evaluation and treatment of orthostatic hypotension Am Earn Physician. 56 1997 1378 1384
19. Ooi W.L., Barrett S., and Hossain M. Patterns of orthostatic blood pressure change and their clinical correlates in a frail, elderly population JAMA 277 1997 1299 1304
20. Empana J.P., Dargent-Molina P., Breart G. EPIDOS Group Effect of hip fracture on mortality in elderly women: The EPIDOS prospective study J Am Geriatr Soc. 52 2004 685 690
21. Saxena P., and Shankar J. Contralateral hip fractures-can predisposing factors be determined? Injury 31 2000 421 424
22. [published correction appears in Br J Urol. 1998;81:510] Buzelin J.M., Fonteyne E., Kontturi M. European Tamsulosin Study Group Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction(symptomatic benign prostatic hyperplasia) Br J Urol 80 1997 597 605
23. Langer S.Z. History and nomenclature of alpha, adrenoceptors Eur Urol. 36 Suppl 1 1999 2 6
24. Schwinn D.A. Novel role for alpha, -adrenergic receptor subtypes in lower urinary tract symptoms BJU Int. 86 Suppl 2 2000 11 20
25. Schwinn D.A., and Michelotti G.A. Alpha,-adrenergic receptors in the lower urinary tract and vascular bed: Potential role for the alphald subtype in filling symp toms and effects ofageing on vascular expression BJU Int. 85 Suppl 2 2000 6 11
26. Schwinn D.A. The role of alpha,-adrenergic receptor subtypes in lower urinary tract symptoms BJU Int. 88 Suppl 2 2001 27 34
27. Kobayashi S., Tang R., Shapiro E., and Lepor H. Characterization and localization of prostatic alpha 1 adrenoceptors using radioligand receptor binding on slide-mounted tissue section J Urol. 150 1993 2002 2006
28. Kawabe K. Current status of research on prostateselective alpha 1-antagonists Br J Urol. 81 Suppl 1 1998 48 50
29. Price D.T., Schwinn D.A., and Lomasney J.W. Identification, quantification, and localization of mRNA for three distinct alpha, adrenergic receptor subtypes in human prostate J Urol. 150 1993 546 551
30. Hieble J.P., Bylund D.B., and Clarke D.E. International Union of Pharmacology. X. Recommendation for nomenclature of alpha 1-adrenoceptors: Consensus update Pharmacol Rev. 47 1995 267 270
31. 1D- adrenoceptors in hyperplastic and non-hyperplastic human prostate J Urol. 161 1999 635 640
32. [in Spanish] Gonzalez Enguita C., Vela Navarrete R., and Salcedo de Diego A. Categorization of adrenergic alpha 1 receptors in detmsor of patients with obstructive BPH. Initial study on experimental animal model Actas Urol Esp. 27 2003 684 691
33. Hampel C., Dolber P.C., and Smith M.P. Modulation of bladder alphai adrenergic receptor subtype expression by bladder outlet obstruction J Urol. 167 2002 1513 1521
34. Terzic A., Puceat M., Vassort G., and Vogel S.M. Cardiac alpha 1-adrenoceptors: An overview Pharmacol Rev. 45 1993 147 175
35. Rudner X.L., Berkowitz D.E., and Booth J.V. Subtype specific regulation of human vascular alpha, adrenergic receptors by vessel bed and age Circulation 100 1999 2336 2343
36. Ruffolo R.R. Jr. Distribution and function of peripheral alpha-adrenoceptors in the cardiovascular system Pharmacol Biochem Behav. 22 1985 827 833
37. Andersson K.E. Alpha- adrenoceptors and benign prostatic hyperplasia: Basic principles for treatment with alpha-adrenoceptor antagonists World J Urol. 19 2002 390 396
38. Floras J.S. Epinephrine and the genesis of hypertension Hypertension 19 1992 1 18
39. Kim J.R., Kiefe C.I., and Liu K. Heart rate and subsequent blood pressure in young adults: The CARDIA study Hypertension 33 1999 640 646
40. [published correction appears in Arch Intern Med. 1998;158:573] The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure Arch Intern Med. 157 1997 2413 2446
41. Kirby R.S., and Pool J.L. Alpha adrenoceptor blockade in the treatment of benign prostatic hyperplasia: Past, present and future Br J Urol. 80 1997 521 532
42. (Suppl) Blue D., Zinner N., and Grino P. R0700004, a selective alpha 1Aadrenoceptor antagonist, does not improve lower urinary tract symptoms in men with benign prostatic hyperplasia Abstract 1044 J Urol 167 2002 265
43. Chapple C.R., Aubry M.L., and James S. Characterisation of human prostatic adrenoceptors using pharmacology receptor binding and localisation Br J Urol. 63 1989 487 496
44. 1-adrenoceptor antagonists Eur Urol. 36 Suppl 1 1999 48 53
45. Roehrbom C.G., and McConnell J.D. Etiology, pathophysiology, epidemiology and natural history of benign prostatic hyperplasia Walsh P.C. Retik A.B. Vaughan E.D. Jr Wein A.L. Campbell's Urology 2002 WB Saunders Philadelphia 1297 1336
46. Hieble J.P., and Ruffolo R.R. Jr. The use of alpha-adrenoceptor antagonists in the pharmacological management of benign prostatic hypertrophy: An overview Pharmacol Res. 33 1996 145 160
47. De Mey C. Cardiovascular effects of alpha blockers for the treatment of symptomatic BPH Eur Urol. 34 Suppl 2 1998 18 28
48. Roehrbom C.G. Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: Arandomized, placebo-controlled trial Urology 58 2001 953 959
49. van Kerrebroeck P., Jardin A., Laval K.U., van Cangh P., and ALFORTI Study Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia Eur Urol 37 2000 306 313
50. Caine M. Alpha-adrenergic blockers for the treatment of benign prostatic hyperplasia Urol Clin North Am. 17 1990 641 649
51. Kaplan S.A., and Kaplan N.M. Alpha-blockade: Monotherapy for hypertension and benign prostatic hyperplasia Urology 48 1996 541 550
52. [published corrections appear in Drugs. 1995;49:554 and Drugs. 1995;50:559] Fulton B., Wagstaff A.L., and Sorkin E.M. Doxazosin. An update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia Drugs 49 1995 295 320
53. Cooper K.L., McKiernan J.M., and Kaplan S.A. Alpha-adrenoceptor antagonists in the treatment of benign prostatic hyperplasia Drugs 57 1999 9 17
54. Kirby R.S., Andersen M., and Gratzke P. A combined analysis of double-blind trials of the efficacy and tolerability of doxazosin- gastrointestinal therapeutic system, doxazosin standard and placebo in patients with benign prostatic hyperplasia BJU Int. 87 2001 192 200
55. Lepor H., Auerbach S., and Puras-Baez A. A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia J Urol. 148 1992 1467 1474
56. Lepor H., and Lowe F.C. Evaluation and nonsurgical management of benign prostatic hyperplasia Walsh P.C. Retik A.B. Vaughan E.D Jr Wein A.L. Campbell's Urology 2002 WB Saunders Philadelphia 1337 1344
57. Lepor H., Jones K., and Williford W. The mechanism of adverse events associated with terazosin: An analysis of the Veterans Affairs Cooperative Study J Urol. 163 2000 1134 1137
58. Man in't Veld A.L., van der Camme T.J., and van Loon K. Drug treatment of hypertension in the elderly: The role of alpha-adrenoceptor blockade Br J Urol. 81 Suppl 1 1998 21 25
59. Levy D., Walmsley P., and Levenstein M. Principal results of the Hypertension and Lipid Trial (HALT): A multicenter study of doxazosin in patients with hypertension Am Heart J. 131 1996 966 973
60. Kuritzky L. Current approaches to the management of BPH Clin Geriatr. 6 1998 65 74
61. Feb 29 Lepor H., Oesterling J.E., and Wasson J.H. BPH management: Minimal to maximal Patient Care 1996 18 35
62. Lowe F.C., Olson P.J., and Padley R.J. Effects of terazosin therapy on blood pressure in men with benign prostatic hyperplasia concurrently treated with other antihypertensive medications Urology 54 1999 81 85
63. Martell N., Luclue M. HT BPHGroup Doxazosin added to single-drug therapy in hypertensive patients with benign prostatic hypertrophy J Ctin Hypertens (Greenwich) 3 2001 218 223
64. [published correction appears in JAMA. 2002;288:2976] ALLHAT Collaborative Research Group Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: The Antihypertensive and Lipid-Lowering Treatmentto Prevent Heart Attack Trial (ALLHAT) JAMA 283 2000 1967 1975
65. [published correction appears in JAMA. 2003;290:197] Chobanian A.V., Bakris G.L., and Black H.R. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, National High Blood Pressure Education Program Coordinating Committee The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report JAMA 289 2003 2560 2572
66. Andersson K.E., Lepor H., and Wyllie M.G. Prostatic alpha, adrenoceptors and uroselectivity Prostate 30 1997 202 215
67. Forray C., Bard J.A., and Wetzel J.M. The alpha 1adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned humanalpha Ic subtype Mol Pharmacol 45 1994 703 708
68. Kenny B.A., Miller A.M., and Williamson E.L. Evaluation of the pharmacological selectivity profile of alpha 1 adrenoceptor antagonists at prostatic alpha 1 adreno ceptors: Binding, functional and in vivo studies Br J Pharmacol. 118 1996 871 878
69. Noble A.L., Chess-Williams R., and Couldwell C. The effects of tamsulosin, a high affinity antagonist at functional alpha IA- and alpha 1D-adrenoceptor subtypes Br J Pharmacol. 120 1997 231 238
70. Lee E., and Lee C. Clinical comparison of selective and non selective alpha 1A-adrenoreceptor antagonists in benign prostatic hyperplasia: Studies on tamsulosin in a fixed dose and terazosin in increasing doses Br J Urol. 80 1997 606 611
71. Abstract 1052 Lowe F.C., and Djavan B. Prospective, randomized trial to evaluate the side effect profile of tamsulosin vs. terazosin in 1983 men with benign prostatic hyperplasia J Urol. 167 Suppl4 2002 267
72. Na Y.J., Guo Y.L., Gu F.L. Chinese Tamsulosin Study Group Clinical comparison of selective and non-selective alpha 1A-adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: Studies on tamsulosin and terazosin in Chinese patients J Med. 29 1998 289 304
73. Narayan P., and Lepor H. Long-term, open-label, phase III multicenter study of tamsulosin in benign prostatic hyperplasia Urology 57 2001 466 470
74. Lepor H. Tamsulosin Investigator Group Phase III multicenter placebo-controlled study of tamsulosin in benign prostatichyperplasia Urology 51 1998 892 900
75. Narayan P., Tewari A. United States 93-01 Study Group A second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatichyperplasia J Urol. 160 1998 1701 1706
76. Michel M.C., Flannery M.T., and Narayan P. Worldwide experience with alfuzosin and tamsulosin Urology 58 2001 508 516
77. Lyseng-Williamson K.A., Jarvis B., and Wagstaff Ad. Tamsulosin: An update of its role in the management of lower urinary tract symptoms Drugs 62 2002 135 167
78. Flomax capsules. Physicians' Desk Reference 2004 Thomson PER Montvale, NJ 1006 1009
79. van Kerrebroeck P. The efficacy and safety of a new once-a-day formulation of an alpha-blocker Eur Urol. 39 Suppl 6 2001 19 26
80. McKeage K., and Plosker G.L. Alfuzosin: A review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia Drugs 62 2002 633 653
81. Roehrbom C.G., van Kerrebroeck P., and Nordling J. Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: Apooled analysis of three double-blind, placebo-controlled studies BJU Int. 92 2003 257 261
82. Lefevre-Borg F., O'Connor S.E., and Schoemaker H. Alfuzosin, a selective alpha 1-adrenoceptor antagonist in the lower urinary tract Br J Pharroacol. 109 1993 1282 1289
83. Martin D.J., Lluel P., and Pouyet T. Relationship between the effects of alfuzosin on rat urethral and blood pressures and its tissue concentrations Life Sci. 63 1998 169 176
84. 1-adrenoceptor antagonists Eur Urol. 36 Suppl 1 1999 35 41
85. (Suppl) Eckert R.E., Utz J., and Alloussi S. Prostate selectivity of alpha 1 adrenoceptor blocken Abstract 897 J Urol. 161 1999 233
86. Mottet N., Bressolle F., and Delmas V. Prostatic tissual distribution of alfuzosin in patients with benign prostatic hyperplasia following repeated oral administration Eur Urol. 44 2003 101 105
87. (Suppl) Motttet N., Bressolle F., and Costa P. Orally administered alfuzosin (ALF) has a high prostatic diffusion in benign prostatic hyperplasia tissue Abstract 1358 J Urol. 163 2000 305 306
88. Teillac P., Delauche-Cavallier M.C., Attali P. DUALF Group Urinary flow rates in patients with benign prostatic hypertrophy following treatment with alfuzosin Br J Urol. 70 1992 58 64
89. Debruyne F.M., and Van der Poel H.G. Clinical experience in Europe with uroselective alpha, antagonists Eur Urol. 36 Suppl 1 1999 54 58
90. 1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction Eur Urol. 36 1999 1 13
91. van Kerrebroeck P., Jardin A., and van Cangh P. Longterm safety and efficacy of a once-daily formulation of alfuzosin 10 mg in patients with symptomatic benign prostatic hyperplasia: Open-labelextension study Eur Urol. 41 2002 54 61
92. Andersson K.E. The concept of uroselectivity Eur Urol 33 Suppl 2 1998 7 11
93. McConnell J.D., Roehrbom C.G., and Bautista O.M. The long term effects of doxazosin, finasteride and combination therapy on the clinical progression of BPH N Engl J Med. 349 2003 2387 2398.